Asston Pharmaceuticals Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Asston Pharmaceuticals Ltd is ₹ 80.9 as of 30 Apr 15:30 . The P/E Ratio of Asston Pharmaceuticals Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Asston Pharmaceuticals Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Asston Pharmaceuticals Ltd changed from 0 % on March 2022 to 0 % on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2022 to 0 % on March 2025 . This represents a CAGR of 0.0% over 4 years .

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt.
Limited' to contract produce pharmaceutical products for export market.
Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility.
Ferron Lifecare Private Limited, incorporated on 30th January 2020.
Finally, 'Asston Pharmaceuticals Private Limited' was converted into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Asston Pharmaceuticals Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Asston Pharmaceuticals Ltd or Sai Parenterals Ltd?

Market cap of Asston Pharmaceuticals Ltd is 68 Cr while Market cap of Sai Parenterals Ltd is 2,148 Cr

What are the key factors driving the stock performance of Asston Pharmaceuticals Ltd and Sai Parenterals Ltd?

The stock performance of Asston Pharmaceuticals Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Asston Pharmaceuticals Ltd and Sai Parenterals Ltd?

As of May 3, 2026, the Asston Pharmaceuticals Ltd stock price is INR ₹80.9. On the other hand, Sai Parenterals Ltd stock price is INR ₹486.4.

How do dividend payouts of Asston Pharmaceuticals Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Asston Pharmaceuticals Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.